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WS18.1 Failure of eradication therapy of Pseudomonas aeruginosa in
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H.G.M. Heijerman1. 1Haga Teaching Hospital, Pulmonary Diseases, The
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Eradication therapy of an early Pseudomonas aeruginosa lung infection in CF is
currently standard of care. Treatment with tobramycin inhalation solution is proven
to be effective. However, this therapy is not effective in all patients and a signiﬁcant
number of patients are reinfected within a year after eradication [1]. Risk factors for
failure of eradication therapy or reinfection after eradication need to be identiﬁed
in order to reach a higher success of eradication therapy.
Objective: Comparison of P. aeruginosa in nasal and sputum cultures in adult
patients with CF.
Methods: In 91 adult patients with CF nasal cultures were taken in two different
ways. Under endoscopic control cultures from the left and right middle meatus
were taken with a swab. Secondly nasal lavage was performed by inserting a sterile
isotonic saline solution in both nostrils. The subject was asked to expectorate sputum
on the same day.
Results: Of the 91 sputum cultures 43 were negative for P. aeruginosa. However,
despite previous ‘successful’ eradication of P. aeruginosa, in 3 patients nasal
cultures still displayed P. aeruginosa.
Conclusions: Eradication of P. aeruginosa in CF patients can appear successful
according to sputum cultures, but nasal cultures can still reveal P. aeruginosa.
Therefore, nasal cultures may be important in the determination of P. aeruginosa
eradication in CF. Moreover, eradication therapy may be extended with anti-
pseudomonial treatment of the sinonasal area to reach total eradication and decrease
the risk of reinfection.
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Objective: To deﬁne the 3 year course of antibodies against P. aeruginosa (alkaline
protease, elastase, and exotoxin A) in CF patients following ﬁrst microbiological
detection in respiratory samples and the success of eradication therapy.
Methods: All CF patients with ﬁrst-time P. aeruginosa detection between
01.01.2005 and 31.12.2008 were identiﬁed. Microbiological and serological results
of the year before and the 3 following years were retrospectively collected. Antibody
titres <500U were deﬁned as negative, giving a cumulative antibody score between
0 and 3. Success of eradication therapy was deﬁned as complete absence of
P. aeruginosa in the third year after ﬁrst detection.
Patients: Of 382 CF, 59 patients with ﬁrst-time P. aeruginosa detection were
identiﬁed (mean age 8.4). In 40 of these serological and microbiological data were
complete and they were analysed in detail.
Results: Eradication was successful in 25 patients (62.5%), 10 patients were
intermittently infected, 5 patients were chronically infected. Positive antibody titres
preceded microbiological detection in 8 patients (20%). Cumulative antibody titres
in the successfully treated patients were rising insubstantially and declining after
the ﬁrst year (mean values in the ﬁrst, second, third year: 0.23, 0.14, 0.13) but were
signiﬁcantly elevated in intermittently infected patients (0.63, 0.83, 0.75) and in
chronically infected patients (1.4, 2.0, 2.1).
Conclusion: Persistent elevation of antibodies against P. aeruginosa indicated the
failure of eradication therapy. The intensity of anti-pseudomonal antibiotic therapy
should be driven not only by microbiological but also by antibody results.
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Introduction: Transmissible strains (TS) of P. aeruginosa (PA) have been described
in cystic ﬁbrosis (CF) and can be associated with a worse prognosis. We sought
to determine the prevalence and stability of PA strains within the Calgary Adult
CF Clinic using our comprehensive strain databank.
Methods: Initial isolates (II) (from initial adult clinic visit) and ﬁnal isolates (FI)
(from most recent clinic visit, or transplantation/death) were examined by pulsed-
ﬁeld gel electrophoresis (PFGE) and compared against a collection of known TS
and strains from patients with non-CF bronchiectasis (nCF-B).
Results: We generated 636 PFGE proﬁles from 111 CF patients. Of 108 patients
with chronic PA infection, 66 patients had both II and FI spanning 674 patient-years
of clinical/microbiologic follow-up available, whereas 19 patients had only II and
23 FI available for assessment. Only one patient was infected with a known TS, the
Liverpool Epidemic Strain (LES). However, a novel, clonally related complex, we
termed the Prairie Epidemic Strain (PES), was identiﬁed in 29% (31/108) of our
cohort. This strain was present at enrollment in our clinic in 76% of patients. Five
patients acquired this infection during 58 patient-years of follow-up. PES is distinct
from previously described TS and was not observed in 17 patients with nCF-B.
Conclusion: PES has been present in our clinic population since at least 1987, is
unique to CF, establishes chronic infection, can displace other PA strains, and has
been found in patients at the time of transition from other CF clinics across the
Prairies. Studies are currently underway to evaulate the clinical implications of PES
infection.
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Background: A recent national survey of 18 Australian CF centres involving 983 pa-
tients with Pa found that >60% shared indistinguishable genotypes. Although most
shared strains involved small clusters and few CF centres, 2 strains (AUST-01 and
AUST-02) were widely dispersed and encountered frequently. It is uncertain if the
high prevalence of these 2 strains was associated with geographic location and/or local
infection control practices.
Objectives:
i. To examine shared Pa strain diversity across Australian CF centres and geographic
regions;
ii. To determine the impact of infection control and molecular typing surveillance on
AUST-01 and AUST-02 strain prevalence.
Methods: Geospatial relationships between Pa genotypes and residential postcodes
were assessed using ArcGIS software. Infection control practices and molecular typing
surveillance strategies for all centres were also reviewed.
Results: Overall, 73% (161/220) of AUST-01 detections were in South-Eastern
Australia, whereas 87% (150/173) of patients with AUST-02 resided in Queensland
and Western Australia. Despite these geographic trends, in some cities there were
differences in detection rates between CF centres. For example, AUST-01 was found
in 2% and 40% of children attending 2 Brisbane CF centres, QLD/01 and QLD/03,
respectively. Lowest rates of AUST-01 and AUST-02 were recorded in paediatric
centres with strict infection control practices and molecular typing surveillance.
Conclusions: The distribution of shared Pa strains in Australian CF patients cannot
be explained fully by geographic location. Strict infection control is associated with a
reduced prevalence of the most commonly encountered shared strains.
